ECSP19070336A - Arn terapéutico - Google Patents
Arn terapéuticoInfo
- Publication number
- ECSP19070336A ECSP19070336A ECSENADI201970336A ECDI201970336A ECSP19070336A EC SP19070336 A ECSP19070336 A EC SP19070336A EC SENADI201970336 A ECSENADI201970336 A EC SENADI201970336A EC DI201970336 A ECDI201970336 A EC DI201970336A EC SP19070336 A ECSP19070336 A EC SP19070336A
- Authority
- EC
- Ecuador
- Prior art keywords
- therapeutic rna
- therapeutic
- rna
- treatment
- field
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Esta descripción se refiere al campo de los ARN terapéuticos para el tratamiento de cánceres de tumores sólidos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762464981P | 2017-02-28 | 2017-02-28 | |
EP17306089 | 2017-08-23 | ||
US201762597527P | 2017-12-12 | 2017-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19070336A true ECSP19070336A (es) | 2019-10-31 |
Family
ID=61569463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201970336A ECSP19070336A (es) | 2017-02-28 | 2019-09-27 | Arn terapéutico |
Country Status (21)
Country | Link |
---|---|
US (3) | US20200147176A1 (es) |
EP (1) | EP3589308A1 (es) |
JP (4) | JP6949131B2 (es) |
KR (1) | KR20190124750A (es) |
CN (1) | CN110337305A (es) |
AU (1) | AU2018229278A1 (es) |
BR (1) | BR112019017743A2 (es) |
CA (1) | CA3054733A1 (es) |
CL (1) | CL2019002461A1 (es) |
CO (1) | CO2019010355A2 (es) |
CR (1) | CR20190444A (es) |
EC (1) | ECSP19070336A (es) |
IL (1) | IL268894A (es) |
MA (1) | MA47680A (es) |
MX (1) | MX2019010269A (es) |
PE (1) | PE20200735A1 (es) |
PH (1) | PH12019501959A1 (es) |
SG (1) | SG11201907846VA (es) |
TW (1) | TW201842921A (es) |
UY (1) | UY37621A (es) |
WO (1) | WO2018160540A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11802292B2 (en) | 2018-01-05 | 2023-10-31 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20200735A1 (es) * | 2017-02-28 | 2020-07-23 | Sanofi Sa | Arn terapeutico |
EP4253544A3 (en) | 2017-05-18 | 2023-12-20 | ModernaTX, Inc. | Modified messenger rna comprising functional rna elements |
TW202026423A (zh) * | 2018-08-24 | 2020-07-16 | 法商賽諾菲公司 | 用於實體瘤癌症的治療性rna |
CA3125773A1 (en) * | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
SG11202107396RA (en) * | 2019-01-21 | 2021-08-30 | Sanofi Sa | Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers |
CN114728176A (zh) * | 2019-10-09 | 2022-07-08 | 川斯勒佰尔公司 | 信使rna的组合物、方法和使用 |
WO2021213924A1 (en) * | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
US20230295257A1 (en) | 2020-07-24 | 2023-09-21 | Strand Therapeutics Inc. | Lipid nanoparticle comprising modified nucleotides |
EP4234567A1 (en) * | 2020-10-20 | 2023-08-30 | ST Pharm Co., Ltd. | Oligonucleotide for 5'-capped rna synthesis |
US20240166707A1 (en) | 2021-01-08 | 2024-05-23 | Strand Therapeutics Inc. | Expression constructs and uses thereof |
WO2022162027A2 (en) * | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
CN116829578A (zh) * | 2021-10-08 | 2023-09-29 | 苏州艾博生物科技有限公司 | 编码白细胞介素-12(il-12)的多核苷酸以及其相关组合物和方法 |
CN116179549A (zh) | 2021-12-08 | 2023-05-30 | 南京吉迈生物技术有限公司 | 通过5’utr序列变体修饰基因转录和翻译效率 |
WO2023212618A1 (en) | 2022-04-26 | 2023-11-02 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
CN117327709A (zh) * | 2022-06-24 | 2024-01-02 | 深圳瑞吉生物科技有限公司 | 用于实体肿瘤的治疗性mRNA及其应用 |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
WO2024074634A1 (en) * | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024074211A1 (en) * | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
EP1442750B1 (en) | 1997-11-20 | 2012-08-01 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
ES2246314T3 (es) | 2000-01-20 | 2006-02-16 | Universitat Zurich Institut Fur Medizinische Virologie | Administracion intratumoral de moleculas desnudas de acido nucleico que codifican il-12. |
ES2164011B1 (es) | 2000-02-25 | 2003-05-16 | Inst Cientifico Tecnol Navarra | Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos. |
EP1800697B1 (de) | 2001-06-05 | 2010-04-14 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie |
US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
WO2003059381A2 (en) | 2002-01-18 | 2003-07-24 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
DE10248141B4 (de) | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nukleinsäuren und deren Verwendung für die Gentherapie |
DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
LT2578685T (lt) | 2005-08-23 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
DK2201100T3 (en) | 2007-09-14 | 2016-05-30 | Univ Bruxelles | IMPROVING THE T-CELL STIMULATING ABILITY OF HUMAN antigen presenting cells AND USE THEREOF IN THE VACCINATION |
US20130108663A1 (en) | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
EP3346005A1 (en) | 2008-01-31 | 2018-07-11 | CureVac AG | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
EP2268306A2 (en) | 2008-03-14 | 2011-01-05 | The Board Of Trustees Of The University Of Illinois | Therapeutic cancer antigens |
WO2009149539A1 (en) | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US8808982B2 (en) | 2009-12-07 | 2014-08-19 | Cellscript, Llc | Compositions and methods for reprogramming eukaryotic cells |
CA2794196A1 (en) | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
PT2590676T (pt) | 2010-07-06 | 2016-11-04 | Glaxosmithkline Biologicals Sa | Partículas de transferência de tipo virião para moléculas de arn auto-replicante |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
CA2850575C (en) | 2011-10-11 | 2020-12-15 | Universitat Zurich Prorektorat Mnw | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
AU2013243951A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
MX365527B (es) * | 2012-10-24 | 2019-06-06 | Us Health | Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r. |
US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
EP3446712A1 (en) | 2013-03-14 | 2019-02-27 | Translate Bio Ma, Inc. | Cftr mrna compositions and related methods and uses |
CN105339389B (zh) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
HUE046469T2 (hu) | 2013-08-21 | 2020-03-30 | Curevac Ag | Készítmény és vakcina tüdõrák kezelésére |
WO2015024664A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition and vaccine for treating prostate cancer |
JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗pd−1抗体並びにその治療及び診断のための使用 |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CN105026428B (zh) | 2013-12-12 | 2018-01-16 | 上海恒瑞医药有限公司 | PD‑l抗体、其抗原结合片段及其医药用途 |
EP3083666A4 (en) | 2013-12-18 | 2017-09-20 | Intrexon Corporation | Single chain il-12 nucleic acids, polypeptids, and uses thereof |
GB2517521B (en) | 2013-12-19 | 2015-07-29 | Anacail Ltd | Drain decontamination system |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CN105031630A (zh) * | 2014-04-28 | 2015-11-11 | 四川大学 | 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法 |
WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
WO2016112983A1 (en) * | 2015-01-15 | 2016-07-21 | Biontech Ag | Cytokine fusion proteins |
MX2017013321A (es) | 2015-04-22 | 2018-07-06 | Curevac Ag | Composicion que contiene arn para tratamiento de enfermedades tumorales. |
EP3289083A4 (en) | 2015-04-27 | 2018-12-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
DK3328419T3 (da) | 2015-07-30 | 2021-10-11 | Macrogenics Inc | Pd-1-bindingsmolekyler og fremgangsmåder til anvendelse deraf |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
US11034752B2 (en) | 2015-08-12 | 2021-06-15 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
EA201890630A1 (ru) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | Антитела против pd-1 и способы их применения |
PL3370768T3 (pl) | 2015-11-03 | 2022-06-13 | Janssen Biotech, Inc. | Przeciwciała specyficznie wiążące pd-1 i ich zastosowania |
WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
EP3500295A2 (en) | 2016-08-19 | 2019-06-26 | CureVac AG | Rna for cancer therapy |
PE20200735A1 (es) | 2017-02-28 | 2020-07-23 | Sanofi Sa | Arn terapeutico |
TW202026423A (zh) | 2018-08-24 | 2020-07-16 | 法商賽諾菲公司 | 用於實體瘤癌症的治療性rna |
CA3125773A1 (en) | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
SG11202107396RA (en) | 2019-01-21 | 2021-08-30 | Sanofi Sa | Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers |
-
2018
- 2018-02-27 PE PE2019001764A patent/PE20200735A1/es unknown
- 2018-02-27 CR CR20190444A patent/CR20190444A/es unknown
- 2018-02-27 TW TW107106479A patent/TW201842921A/zh unknown
- 2018-02-27 KR KR1020197028213A patent/KR20190124750A/ko active IP Right Grant
- 2018-02-27 CN CN201880013857.3A patent/CN110337305A/zh active Pending
- 2018-02-27 SG SG11201907846VA patent/SG11201907846VA/en unknown
- 2018-02-27 JP JP2019546924A patent/JP6949131B2/ja active Active
- 2018-02-27 MA MA047680A patent/MA47680A/fr unknown
- 2018-02-27 MX MX2019010269A patent/MX2019010269A/es unknown
- 2018-02-27 WO PCT/US2018/019878 patent/WO2018160540A1/en unknown
- 2018-02-27 BR BR112019017743A patent/BR112019017743A2/pt not_active IP Right Cessation
- 2018-02-27 AU AU2018229278A patent/AU2018229278A1/en not_active Abandoned
- 2018-02-27 UY UY0001037621A patent/UY37621A/es not_active Application Discontinuation
- 2018-02-27 EP EP18709243.2A patent/EP3589308A1/en active Pending
- 2018-02-27 CA CA3054733A patent/CA3054733A1/en active Pending
-
2019
- 2019-08-25 IL IL26889419A patent/IL268894A/en unknown
- 2019-08-26 CL CL2019002461A patent/CL2019002461A1/es unknown
- 2019-08-27 US US16/552,248 patent/US20200147176A1/en not_active Abandoned
- 2019-08-27 PH PH12019501959A patent/PH12019501959A1/en unknown
- 2019-09-25 CO CONC2019/0010355A patent/CO2019010355A2/es unknown
- 2019-09-27 EC ECSENADI201970336A patent/ECSP19070336A/es unknown
-
2021
- 2021-03-10 JP JP2021037923A patent/JP7201725B2/ja active Active
- 2021-04-30 US US17/245,605 patent/US11865159B2/en active Active
-
2022
- 2022-12-21 JP JP2022203863A patent/JP7461449B2/ja active Active
-
2023
- 2023-11-21 US US18/516,006 patent/US20240173382A1/en active Pending
-
2024
- 2024-03-22 JP JP2024045866A patent/JP2024073650A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11802292B2 (en) | 2018-01-05 | 2023-10-31 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
Also Published As
Publication number | Publication date |
---|---|
JP7201725B2 (ja) | 2023-01-10 |
JP6949131B2 (ja) | 2021-10-13 |
CL2019002461A1 (es) | 2020-01-17 |
US20210290730A1 (en) | 2021-09-23 |
CO2019010355A2 (es) | 2019-10-09 |
US11865159B2 (en) | 2024-01-09 |
KR20190124750A (ko) | 2019-11-05 |
JP2020509016A (ja) | 2020-03-26 |
MA47680A (fr) | 2020-01-08 |
TW201842921A (zh) | 2018-12-16 |
UY37621A (es) | 2018-09-28 |
PE20200735A1 (es) | 2020-07-23 |
EP3589308A1 (en) | 2020-01-08 |
US20240173382A1 (en) | 2024-05-30 |
PH12019501959A1 (en) | 2020-07-06 |
CN110337305A (zh) | 2019-10-15 |
MX2019010269A (es) | 2019-10-14 |
JP2023030083A (ja) | 2023-03-07 |
US20200147176A1 (en) | 2020-05-14 |
BR112019017743A2 (pt) | 2020-04-07 |
CR20190444A (es) | 2019-12-17 |
AU2018229278A1 (en) | 2019-10-17 |
JP2021098735A (ja) | 2021-07-01 |
JP2024073650A (ja) | 2024-05-29 |
CA3054733A1 (en) | 2018-09-07 |
SG11201907846VA (en) | 2019-09-27 |
WO2018160540A1 (en) | 2018-09-07 |
JP7461449B2 (ja) | 2024-04-03 |
IL268894A (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19070336A (es) | Arn terapéutico | |
CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
CL2019000511A1 (es) | Inhibidores de procesos metabólicos celulares. | |
ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
UY37870A (es) | Inhibidores de kras g12c y métodos para utilizarlos campo de la invención | |
BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
CR20150316A (es) | Compuestos y sus métodos de empleo | |
NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
BR112016025427A2 (pt) | processos de preparação de um inibidor de jak1 e formas do mesmo | |
CL2017000506A1 (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
CL2017000659A1 (es) | Inhibidores de histona desmetilasa | |
BR112017022281A2 (pt) | métodos para tratar câncer | |
EA201791391A1 (ru) | Способы получения соединения диарилтиогидантоин | |
NI201800043A (es) | Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1 | |
CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
WO2014113407A3 (en) | Use of small molecule inhibitors targeting eya tyrosine phosphatase | |
BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
CL2019001717A1 (es) | Anticuerpos contra el lif y usos de los mismos. |